肿瘤中心总支副书记、肿瘤Ⅰ科书记兼副主任（牵头）

崇尚科学、规范、人性的医疗理念。善于运用最先进的科学理论、循证医学证据和高端放疗、靶向、免疫、化疗等临床技术，精准诊治胸部肿瘤、消化系统肿瘤、泌尿生殖系统肿瘤；与欧洲、美国的多家机构合作，主持、参与多项临床研究和转化性研究，根据患者具体情况制定精准、规范化临床诊疗计划。

兼任中国抗癌协会肿瘤放射治疗专委会肺癌学组委员 ； 华人放疗协作组（C-RTOG）肺癌专委会委员 ； 中国抗癌协会肺癌专业委员会委员 ； 湖北省临床肿瘤学会（ESCO）第二届理事会常务理事 ； 湖北省临床肿瘤学会（ESCO）肺癌专委会常委； 湖北省临床肿瘤学会（ESCO）肺癌青年专委会主委； 湖北省临床肿瘤学会（ESCO）纵隔肿瘤专委会副主委； 湖北省临床肿瘤学会（ESCO）分子影像专委会常委； 湖北省临床肿瘤学会（ESCO）食管癌专委会常委； 湖北省肿瘤专科联盟第一届理事会副理事长； 湖北省抗癌协会第八届理事会常务理事； 湖北省抗癌协会肿瘤内科治疗专委会副主委； 湖北省抗癌协会肿瘤营养与代谢专委会副主委 ； 湖北省抗癌协会肺癌专委会常委兼秘书 ； 获湖北省自然科学优秀学术论文二等奖1项；黄石市科技进步二等奖1项；武汉大学人民医院“医疗菁英”、“人民抗疫英模”等荣誉；

1.Zhou Jin, Zheming Liu, Huibo Zhang, Tianyu Lei, Jiahui Liu, Yaqi Zhao, Yi Yao*, Qibin Song*. BACH1: A potential predictor of survival in early-stage lung adenocarcinoma. Oxid Med Cell Longev. 2021, in press

2.Tan W#, Jiang P#, Zhang W#, Hu Z, Lin S, Chen L, Li Y, Peng C, Li Z, Sun A, Chen Y, Zhu W, Xue Y, Yao Y, Li X, Song Q, He F*, Qin W*, Pei H*. Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation. Mol Cell. 2021; 81(9): 1890-1904

3.Siqi Yang#, Yi Yao#,*, Yi Dong, et al. Predict radiation pneumonitis using a genome-scale flux analysis on RNA-seq derived from peripheral blood. Front Med. 2021, 8: 715961

4.Bin Xu#, Kehan Song#, Yi Yao#, et al. Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Sci. 2021, 112(6): 2522-2532.

5.Gong Hongyun, Feng Hongyan, Yu Lushi, Tu Ning, Wang Tao, Yao Yi, Wei Yuehua, Wang Yi, Hu Weiguo, Li Xiangpan, Fu Zhenming, Song Qibin, Bulihong. Coronavirus disease 2019 infection among medical staff in Wuhan: a retrospective study from a single center. Chest, 2020, 158(4): 1409-1412

6.Zhaohua Hu, Shaojie Mi, Ting Zhao, Changmin Peng, Yihan Peng, Lulu Chen, Wenge Zhu, Yi Yao, Qibin Song, Xiangpan Li, Xinzhi Li, Chenxi Jia, Huadong Pei. BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites. The EMBO Journal. 2020, 39(12): e104133.

7.Yi Yao#, Yuxin Chu#, Bin Xu, et al. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. Biosci Rep. 2019, 39(6): BSR20190288.

8.Yihan Peng, Qingchao Liao, Wei Tan, Changmin Peng, Zhaohua Hu, Yali Chen, Zhuqing Li, Jing Li, Bei Zhen, Wenge Zhu, Xiangpan Li, Yi Yao, Qibin Song, Chengsheng Liu, Xiangdong Qi*, Fuchu He*, Huadong Pei*. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors. Nat Comm. 2019, 10(1): 1224.

9.Suofu Ye#, Xiaofeng Chen#, Yi Yao#,*, et al. Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study. Sci Rep. 2019, 9(1): 2652

10.Yi Yao#, Yuxin Chu#, Bin Xu, et al. Radiotherapy after surgery has significant survival benefits for patients with triple negative breast cancer. Cancer Med. 2019, 8(2): 554-563.

11.Yi Yao#,*, Min Peng#, Qinglin Shen#, et al. Detecting EGFR Mutations and ALK/ROS1 Rearrangements in Non-Small Cell Lung Cancer Using Malignant Pleural Effusion Samples. Thorac Cancer. 2019, 10(2): 193-202

12.Zhang Chao#, Zeng Wenfeng#, Yao Yi#, Xu Bin, Wei Xiuli, Wang Luoyang, Yin Xiaozhe, Apurba K Barman, Zhang Fayun, Zhang Chunling, Song Qibin*, Liang Wei*. Naringenin ameliorates radiation-induced lung injury by lowering IL-1β level. J Pharmacol Exp Ther. 2018, 366(2): 341-348.

13.Yao Y#,*, Zheng ZL, Song QB. Mesenchymal stem cells: a double-edged sword in radiation-induced lung injury. Thorac Cancer. 2018, 9(2): 208-217.

14.Yao Y, Song Q, Chu Y, et al. Infusion of allogeneic umbilical cord blood hematopoietic stem cells in patients with chemotherapy-related myelosuppression. Exp Ther Med. 2014, 8(6): 1946-1950.